
|Videos|December 22, 2017
Dr. Wang Discusses Acalabrutinib in MCL
Author(s)Michael Wang, MD
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.
Advertisement
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).
Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.
Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































